Myconormin (Terbinafine)

Terbinafine, the active ingredient in Myconormin, is a allylamine antifungal presented as an oral tablet for oral use. It treats dermatophyte skin infections and onychomycosis in adult patients.

GNH USA supplies Myconormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myconormin, an allylamine antifungal, is indicated for infections caused by dermatophyte fungi. - Tinea pedis (athlete's foot): Reduces fungal growth, relieving itching, scaling and redness. - Tinea corporis (ringworm): Clears skin lesions by inhibiting fungal cell membrane synthesis. - Onychomycosis (fungal nail infection): Improves nail appearance and halts further fungal invasion.

Terbinafine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort or diarrhea. - Headache: mild to moderate intensity. - Skin rash or pruritus: localized itching or erythema. - Taste disturbance: altered taste perception or loss of taste. - Elevated liver enzymes: mild, transient increases in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or dark urine. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia, thrombocytopenia or anemia. - Peripheral neuropathy: numbness or tingling in extremities. - Visual disturbances: blurred vision or photophobia.

Before initiating therapy, consider the following safety measures. - Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Avoid in known hypersensitivity: discontinue if allergic reactions develop. - Use cautiously in the elderly: monitor for increased adverse effects. - Review concomitant medications: evaluate potential drug‑drug interactions. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Terbinafine may interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reducing terbinafine exposure. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase terbinafine plasma levels. - Cimetidine: may elevate terbinafine concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Oral contraceptives: possible reduction in contraceptive efficacy. - Antacids containing aluminum or magnesium: may affect absorption, advise spacing doses.